



# Jagsonpal Pharmaceuticals Ltd

**Corporate Office:** Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India)

**Ph.:** +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com  
**CIN. :** L74899DL1978PLC009181



January 13, 2026

<p>The Department of Corporate Services- Listing <b>BSE Ltd,</b> Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 <b>Scrip Code: 507789</b></p>	<p>The Department of Corporate Services- Listing <b>National Stock Exchange of India Ltd</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 <b>Symbol: JAGSNPHARM</b></p>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Subject: Intimation of Board Meeting under Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/ Madam,

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Meeting of the Board of Directors of Jagsonpal Pharmaceuticals Limited (“the Company”) is scheduled to be held on Wednesday, January 21, 2026 to consider and approve, inter-alia the Unaudited Financial Results of the company for the quarter and nine months ended December 31, 2025.

Further, in continuation of our letter dated December 26, 2025, regarding Intimation of closure of Trading Window, we would like to inform that the trading window for trading in Securities of the company shall remain closed till January 23, 2026.

We request you to take the above on record.

Thanking you,

Yours faithfully,

**For Jagsonpal Pharmaceuticals Limited**

**Pratham Rawal**  
**Company Secretary & Compliance Officer**